The Cooper Companies, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bearish -45

Why is CooperCompanies Stock Down 15% Today?

AI-generated analysis

πŸ“‰ Cooper Companies stock fell roughly 13.9% after reporting Q3 adjusted earnings of $1.15 per share which beat estimates but missed on top-line revenue of $1.07 billion.

πŸ’Έ The company provided weak fourth-quarter guidance with a forecast of $1.05 to $1.09 per share, well below the Wall Street estimate of $1.19.

🚫 Investors were disappointed by the decision to retain CooperSurgical instead of selling the unit, removing a potential deal catalyst that had driven the stock price up.

πŸ‘οΈ The CooperVision segment faces continued pressure in Q4 due to lower inventory levels at U.S. contact-lens distributors causing destocking issues.

βš–οΈ Management noted that keeping the surgical side might buffer short-term earnings but could make the company less attractive for long-term investors compared to a sale.

πŸ“… The earnings report and strategic review were released on September 9, with stock prices reacting negatively by early morning trading on September 10, 2026.

Bullish Signals
  • Cooper Companies reported adjusted earnings of $1.15 per share for the third quarter, which beat Wall Street estimates despite missing on top-line revenue.
  • Retaining the CooperSurgical business unit may provide a buffer to earnings in the short term compared to a potential sale.
Risk Factors
  • The company's fourth-quarter revenue forecast of $1.05 to $1.09 per share came in well below Wall Street's consensus estimate of $1.19.
  • U.S. distributor destocking for the CooperVision contact-lens business will continue to hurt fourth-quarter numbers through the end of fiscal 2026.
  • The decision to not sell CooperSurgical removed a potential deal catalyst that had previously driven up the stock price, leading to investor disappointment.
Full Analysis
Cooper Companies (NASDAQ: COO) shares dropped approximately 13.9% following its September 9 earnings report, which delivered mixed results and weak forward guidance. While the company reported adjusted earnings of $1.15 per share that beat analyst estimates, top-line revenue of $1.07 billion missed expectations. The primary driver of the stock decline was a fourth-quarter earnings forecast ranging from $1.05 to $1.09 per share, significantly below Wall Street's consensus estimate of $1.19. The company also disappointed investors by announcing it would retain its surgical business unit, CooperSurgical, rather than selling it as previously anticipated. This decision removed a potential deal catalyst that had driven up the stock price in anticipation of a transaction. Additionally, the medical-device firm warned that destocking at U.S. contact-lens distributors for its CooperVision segment would continue to negatively impact fourth-quarter revenue. Despite the beat on earnings per share, the combination of weak top-line growth and the decision to keep the surgical unit created a double disappointment for shareholders. Management indicated that while retaining CooperSurgical might provide short-term earnings buffering, it could make the stock less attractive in the long term compared to a potential sale. The broader market context saw the S&P 500 and Nasdaq Composite down slightly, but COO's decline was specific to its own operational and strategic news.